Ingredients

B. lactis BL-04®: Benefits, Dosage, Evidence & Side Effects (2026)

What Is B. lactis BL-04®? Bifidobacterium animalis subsp. lactis BL-04® is a specific, proprietary strain of probiotic bacteria belonging to the genus Bifidobacterium. It is a gram-positive, anaerobic microorganism that naturally inhabits…

What Is B. lactis BL-04®?

Bifidobacterium animalis subsp. lactis BL-04® is a specific, proprietary strain of probiotic bacteria belonging to the genus Bifidobacterium. It is a gram-positive, anaerobic microorganism that naturally inhabits the human gastrointestinal tract and is among the most extensively studied probiotic strains available in dietary supplement form. The strain was isolated and characterized for its stability and ability to survive transit through the digestive system, including exposure to stomach acid and bile salts.

Bifidobacterium species are among the first bacteria to colonize the infant gut and remain important members of the adult microbiome throughout life. BL-04® is cultivated through controlled fermentation processes and is widely used in clinical research and commercial probiotic products. It is distinct from other B. lactis strains; strain identity matters significantly in probiotic science, as different strains of the same species can have substantially different effects.

How B. lactis BL-04® Works

Like other probiotic strains, BL-04® is thought to exert its effects through several overlapping mechanisms, though the full picture is not yet completely understood.

  • Gut microbiome modulation: BL-04® may help support a balanced composition of gut bacteria by competing with potentially harmful microorganisms for adhesion sites along the intestinal lining and for available nutrients.
  • Immune system interaction: The gastrointestinal tract houses a significant portion of the body’s immune tissue. Research suggests BL-04® may interact with gut-associated lymphoid tissue (GALT), potentially influencing immune signaling pathways, including the regulation of secretory immunoglobulin A (sIgA), a key antibody in mucosal immunity.
  • Intestinal barrier support: Some laboratory and clinical evidence suggests that certain Bifidobacterium strains may help reinforce tight junction proteins that maintain the integrity of the intestinal lining, potentially reducing permeability.
  • Short-chain fatty acid (SCFA) production: By fermenting dietary fibers, BL-04® may contribute to the production of SCFAs such as acetate, which serve as energy sources for colonocytes and may play a role in local and systemic inflammation regulation.

It is important to note that these mechanisms are based on a combination of in vitro, animal, and human studies, and not all findings from laboratory settings translate directly to measurable clinical outcomes in humans.

Evidence & Research

The overall level of evidence for BL-04® is moderate to mixed, with some areas showing more robust data than others.

Respiratory health: One of the more frequently cited areas of research involves upper respiratory tract infections. A randomized, double-blind, placebo-controlled trial published in the British Journal of Sports Medicine found that physically active individuals taking BL-04® experienced a significant reduction in the incidence of upper respiratory illness compared to placebo. This is considered reasonably strong evidence within its scope, though replication in broader populations is still needed.

Immune function: Several studies suggest BL-04® may support immune markers, particularly sIgA levels and aspects of innate immune response. Evidence here is promising but based on a limited number of trials.

Antibiotic-associated diarrhea: Some data support the use of B. lactis strains generally for reducing antibiotic-associated gastrointestinal disturbances, though strain-specific data for BL-04® specifically remains limited in this area.

Gut health and digestion: Evidence for digestive benefits such as bloating, transit time, or irritable bowel symptoms is preliminary and inconsistent for this specific strain.

Overall, while BL-04® has more human clinical data than many probiotic strains, the total number of high-quality trials remains modest, and further independent research is needed.

Typical Dosage

In clinical studies, BL-04® has most commonly been used in doses ranging from approximately 1 billion to 2 billion colony-forming units (CFU) per day, often listed as 1 × 10⁹ CFU. Some commercial formulations include higher amounts as part of multi-strain blends.

Dosage ranges can vary considerably depending on the intended use, the product formulation, and the population studied. There is currently no universally established optimal dose. Individuals should refer to the dosing used in studies relevant to their area of interest and consult a healthcare provider, as appropriate dosage is highly context-dependent.

Potential Benefits

  • Research suggests BL-04® may help reduce the frequency of upper respiratory tract infections, particularly in physically active individuals.
  • Studies indicate it may support aspects of immune function, including mucosal antibody production.
  • It may help maintain a more balanced gut microbial composition during periods of disruption, such as antibiotic use.
  • Some evidence suggests potential support for general digestive comfort, though this is less well established for this strain specifically.

Side Effects & Safety

BL-04® is generally considered safe for healthy adults. The most commonly reported side effects, when they occur, are mild and gastrointestinal in nature, including temporary bloating, gas, or changes in bowel habits, particularly during the first few days of use as the gut microbiome adjusts.

Serious adverse events have not been reported in published clinical trials at standard doses. However, probiotic safety data, including for this strain, is most robust in healthy adult populations. Long-term safety data beyond several months of use is more limited.

In rare cases, probiotic bacteria have been associated with systemic infections (bacteremia or sepsis) in severely immunocompromised individuals, though this risk is considered very low with Bifidobacterium species compared to some other probiotic genera.

Who Should Avoid It

  • Severely immunocompromised individuals: People with conditions such as advanced HIV/AIDS, those undergoing chemotherapy, or organ transplant recipients on immunosuppressive therapy should consult a physician before using any probiotic, including BL-04®.
  • Individuals with central venous catheters: These individuals may face an elevated theoretical risk of translocation-related infection.
  • Pregnant and breastfeeding individuals: While Bifidobacterium strains are generally regarded as low-risk, clinical data specific to BL-04® in pregnancy is limited. Consultation with a healthcare provider is advisable.
  • Infants and young children: Probiotic use in pediatric populations should be guided by a pediatrician, as dosing and safety profiles differ from adults.
  • Those with serious gastrointestinal conditions: Individuals with conditions such as short bowel syndrome or active inflammatory bowel disease flares should seek medical advice before using probiotics.

Scientific References

Peer-reviewed studies on B. lactis BL-04® are indexed on PubMed (National Library of Medicine).

Supplements Containing B. lactis BL-04®

You can find B. lactis BL-04® in these products we have reviewed:

🕸️ Explore Our Research Web

More Reviews